Dr. Stephenson on the Impact of Active Surveillance in Prostate Cancer

Video

In Partnership With:

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.

There has been an important paradigm shift in the management of this disease, Stephenson explains. It positively impacts quality of life compared with other therapies for patients with localized prostate cancer, such as surgery and radiation therapy. There have been important developments evolving the techniques of these treatments, but there is still a negative impact on urinary, bowel, and sexual function by many patients treated with these modalities.

The aggressiveness of prostate cancer has changed substantially, he explains. Therefore, by subjecting all patients to treatment for prostate cancer, clinicians may be subjecting them to harm without any real, clear benefit, Stephenson adds.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD